CytomX Therapeutics (CTMX) Competitors $2.00 -0.12 (-5.66%) Closing price 04:00 PM EasternExtended Trading$2.07 +0.07 (+3.50%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. NRIX, IMTX, MNMD, BGM, TNGX, QURE, DNA, STOK, TLRY, and PHATShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Nurix Therapeutics (NRIX), Immatics (IMTX), Mind Medicine (MindMed) (MNMD), BGM Group (BGM), Tango Therapeutics (TNGX), uniQure (QURE), Ginkgo Bioworks (DNA), Stoke Therapeutics (STOK), Tilray Brands (TLRY), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Nurix Therapeutics Immatics Mind Medicine (MindMed) BGM Group Tango Therapeutics uniQure Ginkgo Bioworks Stoke Therapeutics Tilray Brands Phathom Pharmaceuticals CytomX Therapeutics (NASDAQ:CTMX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations. Do insiders and institutionals hold more shares of CTMX or NRIX? 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer CTMX or NRIX? CytomX Therapeutics currently has a consensus target price of $5.75, suggesting a potential upside of 187.50%. Nurix Therapeutics has a consensus target price of $28.87, suggesting a potential upside of 193.36%. Given Nurix Therapeutics' higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.81 Which has higher valuation and earnings, CTMX or NRIX? CytomX Therapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$141.10M2.34$31.87M$0.563.57Nurix Therapeutics$54.55M13.79-$193.57M-$2.61-3.77 Does the media refer more to CTMX or NRIX? In the previous week, CytomX Therapeutics had 11 more articles in the media than Nurix Therapeutics. MarketBeat recorded 13 mentions for CytomX Therapeutics and 2 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.56 beat CytomX Therapeutics' score of -0.34 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CTMX or NRIX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Nurix Therapeutics' net margin of -234.57%. CytomX Therapeutics' return on equity of 158.70% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics34.04% 158.70% 36.04% Nurix Therapeutics -234.57%-45.26%-34.71% Which has more risk and volatility, CTMX or NRIX? CytomX Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. SummaryCytomX Therapeutics beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$329.83M$3.07B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio3.5720.4830.7825.12Price / Sales2.34355.18456.64116.46Price / Cash5.2841.5625.2228.45Price / Book-200.009.549.375.95Net Income$31.87M-$54.74M$3.26B$265.46M7 Day Performance7.53%2.39%1.88%0.96%1 Month Performance-15.97%4.60%3.73%2.47%1 Year Performance62.60%9.17%28.93%20.24% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics3.9496 of 5 stars$2.00-5.7%$5.75+187.5%+76.7%$329.83M$141.10M3.57170NRIXNurix Therapeutics2.6153 of 5 stars$9.65-1.9%$28.87+199.1%-54.2%$752.26M$54.55M-3.70300Positive NewsIMTXImmatics1.9191 of 5 stars$6.34+2.6%$14.67+131.3%-46.0%$751.18M$168.65M-37.29260Trending NewsEarnings ReportAnalyst RevisionMNMDMind Medicine (MindMed)2.7484 of 5 stars$10.00+1.5%$24.71+147.1%+53.3%$749.47MN/A-6.5440BGMBGM GroupN/A$7.61-1.2%N/A+47.9%$748.61M$25.10M0.00298TNGXTango Therapeutics1.9364 of 5 stars$6.41-3.0%$10.33+61.2%-27.5%$735.43M$42.07M-4.8290Positive NewsAnalyst ForecastQUREuniQure2.8158 of 5 stars$14.09+6.1%$36.55+159.4%+136.9%$728.63M$27.12M-3.59500Positive NewsDNAGinkgo Bioworks1.1065 of 5 stars$11.87-3.5%$8.50-28.4%N/A$719.36M$227.04M-2.02640STOKStoke Therapeutics4.5333 of 5 stars$13.16+0.5%$25.80+96.0%+26.5%$715.22M$36.56M16.66100Earnings ReportAnalyst ForecastAnalyst RevisionTLRYTilray Brands2.5649 of 5 stars$0.92+41.7%$1.92+108.6%-41.2%$713.91M$821.31M-0.402,842High Trading VolumePHATPhathom Pharmaceuticals2.843 of 5 stars$10.28+5.5%$17.50+70.2%-18.9%$690.99M$55.25M-2.17110 Related Companies and Tools Related Companies Nurix Therapeutics Competitors Immatics Competitors Mind Medicine (MindMed) Competitors BGM Group Competitors Tango Therapeutics Competitors uniQure Competitors Ginkgo Bioworks Competitors Stoke Therapeutics Competitors Tilray Brands Competitors Phathom Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access